Expected pharmaceutical development

RM-581 and its analogues (exclusive licence option granted by Université Laval for several types of cancer). Patent granted in the United States (US11174282B2) and Europe (EP3464317A4), pending in Canada (CA3024351A1).

Our R&D history

RM-581 PIPELINE

  • Steps
  • Discoveries
  • Non-clinical (In vitro)
  • Non-clinical (In vivo)
  • Preclinical (Good Laboratory Practice)
  • Phase I
  • Phase II
Pancreatic cancer*
Prostate cancer (AR+, AR-)*
Breast cancer
Lung cancer (non-small cell, small cell)*
Colon cancer

Eligible type of cancer for the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) accelerated approval program.

R&D HISTORY

Dr. Donald Poirier and his team began work on aminosteroid derivatives in 2000 at the medicinal chemistry laboratory of the Centre de recherche du CHU de Québec-Université Laval. Their expertise in chemical synthesis and medicinal chemistry has enabled them to generate over 700 steroid derivatives and to carry out structure-activity relationship studies that led to the discovery of the RM-581 aminosteroid, an active oral drug for several types of cancer. Dr. Poirier has also obtained over $2M in research grants from various organizations, leading to two patents and the founding of Neolys Pharma to support further research.

2000

Dr Donald Poirier

Research on antileukemic drugs (aminosteroids)

2007

Aminosteroids

Dr. René Maltais joins the team.

2009

Patent RM-133

(Androstane series)

2017

New patent RM-581

(Estrane series)

2022

$840,000 subsidy

Research on RM-581 effectiveness against pancreatic cancer

2023

Neolys Pharma is founded.

Christian Roby joins the team.

Dr. Donald Poirier receives over $2M in research grants from various organizations before founding Neolys Pharma.